Committed to Revolutionizing the Treatment for People Living with Neurodegenerative Diseases to Restore and Protect Neuronal Health

Our Approach

Our Approach

We are a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Our nanotherapeutics target cellular energy impairments that are common to many diseases.

Understand Our Science and Mechanism of Action
Our Pipeline

Our Pipeline

Our nanotherapeutic platform enables the creation of clean-surfaced,
catalytically-active nanocrystals for therapeutic use. We are advancing a pipeline of these nanotherapeutics to address high unmet medical needs, starting with neurodegenerative diseases.

Explore Our Pipeline
Our Team

Our Team

We believe in applying innovations to therapeutic challenges that currently have no effective solutions. With the right mix of experience, expertise, and creativity, we are changing the landscape of clinical development.

Meet Our Team

Global ALS Awareness Day, June 21st

“On Global ALS Awareness Day, we at Clene Nanomedicine are proud to be part of the community working to make a difference to the many impacted by this devastating disease. Together we can help people living with ALS.”

– Jen Hotchkin
Executive Director, Global Marketing and Commercial Planning

“ALS is a debilitating disease that rapidly robs a person of the ability to move, talk, eat, and breathe. At Clene Nanomedicine, we are working very hard, literally round the clock, on an innovative treatment, CNM-Au8, that may prove to bring the world a new way to look at these diseases, through the lens of energetic, catalytic repair. As a scientist at Clene, there’s nothing I want more than to add an important treatment to the arsenal against this brutal disease.”

– Karen Ho, PhD, MSc
Head, Translational Medicine

“We look forward to the continued advancement of the ALS clinical program with lead asset, CNM-Au8®, a gold nanocrystal suspension, with the top-line results from the HEALEY ALS Platform Trial expected in Q3 2022.”

– Austin Rynders
Senior Director, Clinical Operations

“This is an exciting time for Clene as we build a body of scientific and clinical evidence in support of CNM-Au8 in neurodegenerative diseases.”

– Allison Widlitz, MS, PA-C
VP, Medical Affairs